Jinglan Pei
YOU?
Author Swipe
View article: Quantifying cortical lesions in large legacy multiple sclerosis clinical trial MRI datasets using multi-contrast post-processing and deep learning
Quantifying cortical lesions in large legacy multiple sclerosis clinical trial MRI datasets using multi-contrast post-processing and deep learning Open
Multiple sclerosis (MS) is a chronic neurological disease affecting both white and gray matter of the central nervous system. Despite the well-established history of gray matter involvement in MS, cortical lesions are almost never evaluate…
View article: Longitudinal study of immunity to<scp>SARS‐CoV2</scp>in ocrelizumab‐treated<scp>MS</scp>patients up to 2 years after<scp>COVID</scp>‐19 vaccination
Longitudinal study of immunity to<span>SARS‐CoV2</span>in ocrelizumab‐treated<span>MS</span>patients up to 2 years after<span>COVID</span>‐19 vaccination Open
Objectives (1) To plot the trajectory of humoral and cellular immune responses to the primary (two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple sclerosis (MS) patients up to 2 years post‐vaccination; (2…
View article: Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination
Longitudinal study of immunity to SARS-CoV2 in Ocrelizumab-treated multiple sclerosis patients up to 2 years after COVID-19 vaccination Open
Objectives 1 To plot the trajectory of humoral and cellular immune responses to the primary (two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple sclerosis (MS) patients up to 2 years post-vaccination; 2. t…
View article: Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis
Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis Open
Objective This study aimed to evaluate safety (infusion‐related reactions [IRRs]) and patient satisfaction (patient‐reported outcomes [PROs]) for at‐home ocrelizumab administration for patients with multiple sclerosis (MS). Methods This op…
View article: Hybrid and vaccine‐induced immunity against <scp>SAR‐CoV</scp> ‐2 in <scp>MS</scp> patients on different disease‐modifying therapies
Hybrid and vaccine‐induced immunity against <span>SAR‐CoV</span> ‐2 in <span>MS</span> patients on different disease‐modifying therapies Open
Objective To compare “hybrid immunity” (prior COVID‐19 infection plus vaccination) and post‐vaccination immunity to SARS CoV‐2 in MS patients on different disease‐modifying therapies (DMTs) and to assess the impact of vaccine product and r…
View article: Hybrid and vaccine-induced immunity against SARS-CoV-2 in MS patients on different disease-modifying therapies
Hybrid and vaccine-induced immunity against SARS-CoV-2 in MS patients on different disease-modifying therapies Open
Objective To compare ‘hybrid immunity’ (prior COVID-19 infection plus vaccination) and post-vaccination immunity to SARS CoV-2 in MS patients on different disease-modifying therapies (DMTs) and to assess the impact of vaccine product and r…
View article: Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study
Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study Open
Objective The objective of this study was to determine the impact of multiple sclerosis (MS) disease‐modifying therapies (DMTs) on the development of cellular and humoral immunity to severe acute respiratory syndrome‐coronavirus 2 (SARS‐Co…
View article: Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study
Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies: a multi-ethnic observational study Open
Objective To determine the impact of MS disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to SARS-CoV-2 infection. Methods MS patients aged 18-60 were evaluated for anti-nucleocapsid and anti-Spike RBD …
View article: An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability Open
Background Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may …
View article: Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy
Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy Open
Objective. To assess differences in joint damage and inflammation using magnetic resonance imaging (MRI) between patients with rheumatoid arthritis (RA) who achieved low disease activity with tocilizumab (TCZ) + methotrexate (MTX) and subs…
View article: 274. CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE
274. CLINICAL OUTCOMES OF PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN REAL-WORLD CLINICAL PRACTICE Open
Background: The GiACTA study demonstrated the superiority of subcutaneous tocilizumab (TCZ) plus prednisone vs prednisone alone in achieving sustained glucocorticoid (GC)-free remission in patients with giant cell arteritis (GCA) 1.We aime…
View article: Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial Open
Background: Upper extremity (UE) impairment is common with primary progressive multiple sclerosis (PPMS). Objective: This exploratory analysis examined the effects of ocrelizumab on confirmed progression (CP) and confirmed improvement (CI)…
View article: Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study
Long‐Term Safety of Rituximab in Patients With Rheumatoid Arthritis: Results of a Five‐Year Observational Study Open
Objective To evaluate the long‐term safety of rituximab in an observational cohort of patients with rheumatoid arthritis ( RA ) who had an inadequate response to ≥1 anti–tumor necrosis factor therapy in the US ( SUNSTONE [Study of the Safe…
View article: Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis Open
Objective Randomised controlled trials (RCTs) have shown tocilizumab (TCZ) administered intravenously or subcutaneously with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) to be superior to csDMARDs alone for impro…